Economic Burden of Urinary Incontinence in Men With Prostate Cancer: Results From the Medical Expenditure Panel Survey (2016-2021).
[OBJECTIVE] To evaluate the economic burden of urinary incontinence among prostate cancer survivors using nationally representative data, focusing on differences in healthcare expenditures and utiliza
- p-value P=.004
- 95% CI 1.10-5.50
- 연구 설계 cross-sectional
APA
Slota J, Naser-Tavakolian A, et al. (2026). Economic Burden of Urinary Incontinence in Men With Prostate Cancer: Results From the Medical Expenditure Panel Survey (2016-2021).. Urology, 207, 107-112. https://doi.org/10.1016/j.urology.2025.09.014
MLA
Slota J, et al.. "Economic Burden of Urinary Incontinence in Men With Prostate Cancer: Results From the Medical Expenditure Panel Survey (2016-2021).." Urology, vol. 207, 2026, pp. 107-112.
PMID
40946921
Abstract
[OBJECTIVE] To evaluate the economic burden of urinary incontinence among prostate cancer survivors using nationally representative data, focusing on differences in healthcare expenditures and utilization between survivors with and without incontinence.
[METHODS] We conducted a cross-sectional analysis using 2016-2021 data from the Medicare Expenditure Panel Survey. Men with self-reported prostate cancer were categorized by incontinence status. The primary outcome was the likelihood of incurring above-average total healthcare expenditures. Secondary outcomes included expenditures by care setting and frequency of outpatient visits. Survey-weighted multivariable logistic regression models were utilized to analyze expenditures, adjusting for age, race, insurance status, and education level.
[RESULTS] The final weighted study population represented 3,060,848 prostate cancer survivors (76,759 with incontinence and 2,984,089 without). Survivors with incontinence were more often uninsured (8.9% vs 1.1%; P=.004) and less likely to have private insurance (2.5% vs 14.7%; P=.004). After adjustment, incontinence was associated with higher odds of above-average total expenditures (adjusted odds ratio [aOR] 2.33; 95% confidence interval [CI] 1.18-4.60; P=.015), largely driven by outpatient visits (aOR 3.81; 1.76-2.76; P=.001), outpatient expenditures (aOR 2.46; 95% CI 1.10-5.50; P=.029) and other non-facility-related expenditures (aOR 2.43; 95% CI 1.17-5.08; P=.018). Survivors with incontinence averaged 9 outpatient visits annually versus 6 among those without incontinence (P=.015).
[CONCLUSION] Urinary incontinence significantly increases healthcare utilization and expenditures among prostate cancer survivors, particularly through outpatient care and incontinence-related medical supplies. Targeted strategies to prevent and manage incontinence may reduce long-term economic burden and improve survivorship care.
[METHODS] We conducted a cross-sectional analysis using 2016-2021 data from the Medicare Expenditure Panel Survey. Men with self-reported prostate cancer were categorized by incontinence status. The primary outcome was the likelihood of incurring above-average total healthcare expenditures. Secondary outcomes included expenditures by care setting and frequency of outpatient visits. Survey-weighted multivariable logistic regression models were utilized to analyze expenditures, adjusting for age, race, insurance status, and education level.
[RESULTS] The final weighted study population represented 3,060,848 prostate cancer survivors (76,759 with incontinence and 2,984,089 without). Survivors with incontinence were more often uninsured (8.9% vs 1.1%; P=.004) and less likely to have private insurance (2.5% vs 14.7%; P=.004). After adjustment, incontinence was associated with higher odds of above-average total expenditures (adjusted odds ratio [aOR] 2.33; 95% confidence interval [CI] 1.18-4.60; P=.015), largely driven by outpatient visits (aOR 3.81; 1.76-2.76; P=.001), outpatient expenditures (aOR 2.46; 95% CI 1.10-5.50; P=.029) and other non-facility-related expenditures (aOR 2.43; 95% CI 1.17-5.08; P=.018). Survivors with incontinence averaged 9 outpatient visits annually versus 6 among those without incontinence (P=.015).
[CONCLUSION] Urinary incontinence significantly increases healthcare utilization and expenditures among prostate cancer survivors, particularly through outpatient care and incontinence-related medical supplies. Targeted strategies to prevent and manage incontinence may reduce long-term economic burden and improve survivorship care.
MeSH Terms
Humans; Male; Urinary Incontinence; Prostatic Neoplasms; Cross-Sectional Studies; Aged; Health Expenditures; United States; Cost of Illness; Medicare; Aged, 80 and over; Cancer Survivors